Andere Kunden interessierten sich auch für
![The Birth of Mankynde: Otherwyse Named the Womans Booke.]( "The Birth of Mankynde: Otherwyse Named the Womans Booke.")
The Birth of Mankynde: Otherwyse Named the Womans Booke.26,99 €![Moles, or Birth-marks, and Their Signification to Man and Woman]( "Moles, or Birth-marks, and Their Signification to Man and Woman")
Moles, or Birth-marks, and Their Signification to Man and Woman21,99 €![Promoting Normal Birth]( "Promoting Normal Birth")
Promoting Normal Birth41,99 €![Zero to Birth]( "Zero to Birth")
Zero to Birth22,99 €![A Series of Articles On Speech-Defects As Localizing Symptoms, From a Study of Six Cases of Aphasia / by J.T. Eskridge]( "A Series of Articles On Speech-Defects As Localizing Symptoms, From a Study of Six Cases of Aphasia / by J.T. Eskridge")
A Series of Articles On Speech-Defects As Localizing Symptoms, From a Study of Six Cases of Aphasia / by J.T. Eskridge20,99 €![Stammering and Cognate Defects of Speech; Volume 2]( "Stammering and Cognate Defects of Speech; Volume 2")
Stammering and Cognate Defects of Speech; Volume 227,99 €![Low Birth Weight Babies and Disability]( "Low Birth Weight Babies and Disability")
Low Birth Weight Babies and Disability43,99 €
Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation.